| Drug Name |
Ponesimod |
| Drug ID |
BADD_D02584 |
| Description |
Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults.[A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod].[A232079] Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and so more selective modulators were developed.[A232079]
Ponesimod was granted FDA approval on 18 March 2021.[L32709] |
| Indications and Usage |
Ponesimod is indicated to treat adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[L32709] |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AA50 |
| DrugBank ID |
DB12016
|
| KEGG ID |
D11215
|
| MeSH ID |
C550169
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0Y4SI
|
| NDC Product Code |
50458-707; 50458-720 |
| UNII |
5G7AKV2MKP
|
| Synonyms |
ponesimod | 5-(3-chloro-4-(2,3-dihydroxy-propoxy)benzylidene)-2-propylimino-3-o-tolyl-thiazolidin-4-one | ponvory | ACT 128800 | ACT128800 | ACT-128800 |
